Last reviewed · How we verify

NCT03143491

Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)

Withdrawn Phase 2 Last updated 18 October 2017
What this trial tests

Phase 2 trial testing SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment in Cervical Intraepithelial Neoplasia. Withdrawn.

Timeline
1 October 2017
Primary endpoint
1 December 2018
1 March 2019

Quick facts

Lead sponsorDFB Soria, LLC
PhasePhase 2
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Start date1 October 2017
Primary completion1 December 2018
Estimated completion1 March 2019

Drugs / interventions tested

Conditions studied

Sponsor

DFB Soria, LLC — full company profile →

Who can join

18 and older, female only, with Cervical Intraepithelial Neoplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%) applied topically once per week for four weeks to the ectocervix of subjects with high grade cervical intraepithelial neoplasia (CIN).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment

Trials testing the same drug.

Other recruiting trials for Cervical Intraepithelial Neoplasia

Currently open trials in the same condition.

Other DFB Soria, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03143491.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing